Quick Takeaways
- David D. Chang filed SCHEDULE 13G for Allogene Therapeutics, Inc. Common Stock (ALLO).
- Disclosed ownership: 5.2%.
- Date of event: 31 Dec 2025.
David D. Chang - 31 Dec 2025 SCHEDULE 13G Report for Allogene Therapeutics, Inc. Common Stock (ALLO)
- Filing Manager
- David D. Chang
- Reporting Manager
- David D. Chang, M.D., Ph.D.
- Symbol
- ALLO
- Shares outstanding
- 232,715,827 shares
- Disclosed Ownership
- 12,101,223 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 13 Feb 2026, 16:22:07 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 12 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"David D. Chang disclosed 5.2% ownership in Allogene Therapeutics, Inc. Common Stock (ALLO) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 12 Nov 2025.
- Current filing was accepted on 13 Feb 2026, 16:22.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| David D. Chang, M.D., Ph.D. | 5.2% | 12,101,223 | 9,188,027 | 2,913,196 | /s/ David D. Chang | David D. Chang, M.D., Ph.D. | |
| Chang 2006 Family Trust | 0.5% | 1,201,108 | 0 | 1,201,108 | /s/ David D. Chang | By David D. Chang, M.D., Ph.D., Co-Trustee | |
| JEC 2019 Trust | 0.4% | 856,044 | 0 | 856,044 | /s/ David D. Chang | By David D. Chang, M.D., Ph.D., Co-Trustee | |
| RTC 2019 Trust | 0.4% | 856,044 | 856,044 | 0 | /s/ David D. Chang | By David D. Chang, M.D., Ph.D., Co-Trustee |